New Retina Radio by Eyetube

Could a Wnt pathway agonist match anti-VEGF therapy for DME, and what should we make of a phase 3 trial that hit its anatomic goals but missed its primary visual endpoint? Don D’Amico, MD, reviews one-year results from the phase 2b/3 BRUNELLO study of remigromig (Restoret, Merck/EyeBio), a Wnt pathway agonist, for diabetic macular edema. And Carl Regillo, MD, discusses the phase 3 LUGANO study of EYP-1901 (vorolanib, EyePoint Pharmaceuticals) for wet AMD, which missed its primary endpoint despite reducing treatment burden by 42%.

The debates at AAO Retina Subspecialty Day have a reputation for examining unresolved issues. Where did the debate on whether wet AMD tolerates fluid land? Avni Finn, MD, joined the show to recap her side of the wet AMD fluid debate—and shared what the opposite side had to argue, too. How well does she buy her own argument?

And Darius Moshfeghi, MD, joins the show to share findings from the SOL-1 study examining OTX-TKI (Ocular Therapeutix) for wet AMD. What did the researchers find? And how did the study authors leverage AI to simulate real-world treatment activity? Join us on this episode to find out.

Does phacovitrectomy improve outcomes over conventional PPV for rhegmatogenous retinal detachment repair in a phakic eyes? Or does it introduce unnecessary complexity? Vaidehi Dedania, MD; Yewlin Chee, MD; and Joshua Uhr, MD, review results from a multicenter cohort study published in Ophthalmology Retina and discuss whether the study's findings have any bearing on real-world decision-making, parse generational differences regarding perceived phacovitrectomy risks, and review whether changes to technology during the course of the study may have affected the findings.

Co-hosts Justin C. Muste, MD, and David Fell, MD, are joined by Matthew Starr, MD, a vitreoretinal surgeon at the Mayo Clinic, and Timothy Xu, MD, a retina fellow at Wills Eye Hospital, to discuss retained lens fragments and secondary IOLs. They share complex cases, when to consider following patients medically, surgical techniques for removing fragments, and how to make the best secondary lens choice.

In this episode of RetinaLive focused on UNITY® VCS|CS, Matt Cunningham, MD, FASRS, welcomes Steven Yeh, MD, FASRS for a reflection on early clinical experience with the UNITY® VCS system following the first 50 cases. The discussion highlights real-world insights on surgical efficiency, fluidics stability, and intraoperative control across a range of case complexities. From seamless OR integration to advancements in 27-gauge instrumentation and laser delivery, the conversation offers practical perspectives on adoption, training, and how evolving technology can enhance surgeon confidence and patient care.

Disclaimers:

References:

1. Alcon Data on File, 2025. (REF-28170)

2. UNITY™ VCS and CS User Manual

3. Vasavada V, Agrawal D, Vasavada SA, Vasavada AR, Yagnik J. Intraoperative performance and early postoperative outcomes following phacoemulsification with three fluidic systems: A randomized trial. J Refract Surg. 2024;40(5):e304-e312.

4. Sugiura Y, Okamoto F, Okamoto Y, Hiraoka T, Oshika T. Intraocular pressure fluctuations during microincision vitrectomy with Constellation Vision System. Am J Ophthalmol. 2013;156(5)941-947

5. Alcon data on file 2024. (REF-24576)

6. Alcon data on file 2024 (REF-24615)

7. Alcon data on file 2024 (REF-24379)

9. Alcon data on file 2024 (REF-24644)

10. Alcon data on file 2024. (REF-24615)

11. UNITY™ VCS and CS User Manual Unity Phaco Handpiece Directions for Use.

Sponsored by Alcon, Inc. © 2026 Alcon Inc. 07/26 US-UVC-2600114

How aggressively should you manage a vitreous hemorrhage after a PVD when you can't see the retina underneath it? Barton Blackorby, MD, moderates a discussion with Matt Starr, MD, and Kyle Kovacs, MD, about a study published in Ophthalmology by Hasbolat et al examining 366 patients with PVD-related vitreous hemorrhage initially managed with observation. The panel discusses how exam technique and B-scan reliance may affect detachment detection rates, debates follow-up intervals given that most retinal detachments in the study occurred within the first 3 weeks, and shares their own thresholds for moving to early vitrectomy versus continued observation, including how they counsel patients eager for faster visual recovery.

In this episode of RetinaLive focused on UNITY® VCS|CS, Jay Sridhar, MD is joined by Nina Berrocal, MD for a forward-looking discussion on adopting next-generation surgical technology. The conversation explores how UNITY® VCS is enabling innovation in a new retina practice setting, with a focus on fluidics stability, integrated anterior and posterior segment capabilities, and enhanced intraoperative efficiency. Through real-world perspectives, the episode highlights the role of advanced technology in simplifying surgical workflows, and supporting the training of the next generation of retina surgeons.

Disclaimers:

6:13: *Mean fluctuation at flow vs. setpoint of 2.36 ± 2.13, 4.19 ± 1.97, 1.84 ± 2.82, and 2.13 ± 2.86 mmHg during phacoemulsification, irrigation/aspiration (IA), vitrectomy, and extrusion/fragmentation, respectively. IOP setpoint as low as 16 mmHg (posterior) and 20 mmHg (anterior) without exceeding a mean fluctuation of 4.19 ± 1.97 mmHg

9:08: MSLP(4) is 3 times faster than SSLP

References:

1. UNITY™ VCS and CS User Manual Unity Phaco Handpiece Directions for Use. 

2. Alcon data on file 2024 (REF-24615)

3. Alcon data on file 2024 (REF-24379)

4. Alcon data on file 2024 (REF-24576)

5. Alcon Data on File (REF-27800)

6. UNITY™ VCS and CS User Manual

7. Alcon data on file 2024. (REF-24899)

Sponsored by Alcon, Inc. © 2026 Alcon Inc. 07/26 US-UVC-2600112

Can a single molecule treat both GA and Stargardt Disease? And if so, how far along is the research? Jay Chhablani, MD, joins New Retina Radio to share data from ArMaDa and GARDian, which assessed OCU410 (Ocugen) in geographic atrophy and Stargardt disease, respectively.

And Jordan Deaner, MD, sits down to discuss his research on real-world retinal tears and detachments following YAG capsulotomy. What are the actual incidence rates? And what risk factors were identified? Stick with us to find out.  

What can pharmacovigilance data tell us about the post-marketing safety profiles of anti-VEGF agents, and where do those signals fall short? In this episode of New Retina Radio Journal Club with VBS, Katherine Talcott, MD, moderates a discussion with Akshay Thomas, MD, and Nita Valikodath, MD, MS, on a 2026 study comparing ocular adverse event reporting for aflibercept 2 mg (Eylea, Regeneron), aflibercept 8 mg (Eylea HD, Regeneron), and faricimab (Vabysmo, Genentech/Roche) using the FDA Adverse Event Reporting System. The group examines distinct signal profiles for each agent and makes the case for why these findings should be viewed as hypothesis-generating rather than evidence of causality.

In this episode of New Retina Radio, host Barry Kuppermann, MD, PhD, sits down with Bob Jahr, CEO of Outlook Therapeutics, to discuss the FDA approval of LYTENAVA™ (bevacizumab-vikg), the only FDA-approved ophthalmic bevacizumab formulation for nAMD.1,2 They explore the regulatory journey over the course of more than 8 years,3 the rigorous FDA review process,4 manufacturing and product quality, commercialization plans, payer considerations, and future development. Please see the Important Safety Information and full US Prescribing Information for LYTENAVA.